Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13303929 | 0.89 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3ALDH1A1CNR1 | |
| SCHEMBL13303937 | 0.82 | MAPT (0.46) | MAPTLMNATP53TSHRHTT | |
| SCHEMBL15856940 | 0.82 | CNR2 (0.40) | SLC6A2SLC6A4SLC6A3ALDH1A1CNR1 | |
| SCHEMBL9972864 | 0.77 | MAPT (0.55) | MAPTLMNATP53TSHRHTT | |
| SCHEMBL9972862 | 0.74 | USP2 (0.43) | LMNA | |
| SCHEMBL9972859 | 0.72 | USP2 (0.44) | MAPTLMNATP53TSHRHTT | |
| Mechlorethamine SCHEMBL12802922 | 0.69 | MAPT (0.86) | MAPTLMNATP53TSHRHTT | |
| Mechlorethamine SCHEMBL3861 | 0.69 | — | — | |
| Mechlorethamine SCHEMBL11905424 | 0.69 | MAPT (1.00) | MAPTLMNATP53TSHRHTT | |
| SCHEMBL6167401 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187810-A1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | ACTELION PHARMACEUTICALS, LTD. (CH) | 2014-07-03 | — | — | US | disclosed |
| US-20140187810-A1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | ACTELION PHARMACEUTICALS, LTD. (CH) | 2014-07-03 | — | — | US | disclosed |
| US-8501818-B2 | Stabilized compositions of alkylating agents and methods of using same | CEPTARIS THERAPEUTICS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130184243-A1 | COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH | CEPTARIS THERAPEUTICS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013009800-A2 | COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH | CEPTARIS THERAPEUTICS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
| US-20120157545-A1 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20110039943-A1 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2011-02-17 | — | — | US | disclosed |
| US-20100152300-A1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | HELSINN HEALTHCARE SA (CH) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039943-A1 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS | S100A8, CUTA, S100A4 | MAPT 1744/4885LMNA 2387/4885TP53 1167/4885 |
| US-20100152300-A1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | MGMT, UNG, ERCC5 | MAPT 2619/4885LMNA 2236/4885TP53 22/4885 |
| US-20130184243-A1 | COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH | MGMT, UNG, OGG1 | MAPT 3685/4885LMNA 2267/4885TP53 21/4885 |
| US-20140187810-A1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | MGMT, UNG, ERCC5 | MAPT 2619/4885LMNA 2236/4885TP53 22/4885 |
| US-20120157545-A1 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS | S100A8, CUTA, S100A4 | MAPT 1744/4885LMNA 2387/4885TP53 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.